An overview of the efficacy and signaling pathways activated by stem cell-derived extracellular vesicles in diabetic kidney disease

Lin, Yongda; Yang, Qian; Wang, Jiali; Chen, Xiutian; Liu, Yiping; Zhou, Tian-Biao

doi:10.3389/fendo.2022.962635

Cited by 3 publications

(3 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The contents of these cargoes serve a useful purpose. It was shown that stem cell exos protect the kidney from damage through multiple pathways by eliciting anti-apoptotic, anti-inflammatory, anti-oxidative, and anti-fibrotic effects and by regulating podocyte autophagy ( 230 ). Therefore, MSCExos are expected to be a potential therapeutic option for the treatment of DKD ( 231 ).…”

Section: Treatmentmentioning

confidence: 99%

Tubular injury in diabetic kidney disease: molecular mechanisms and potential therapeutic perspectives

et al. 2023

View full text Add to dashboard Cite

Diabetic kidney disease (DKD) is a chronic complication of diabetes and the leading cause of end-stage renal disease (ESRD) worldwide. Currently, there are limited therapeutic drugs available for DKD. While previous research has primarily focused on glomerular injury, recent studies have increasingly emphasized the role of renal tubular injury in the pathogenesis of DKD. Various factors, including hyperglycemia, lipid accumulation, oxidative stress, hypoxia, RAAS, ER stress, inflammation, EMT and programmed cell death, have been shown to induce renal tubular injury and contribute to the progression of DKD. Additionally, traditional hypoglycemic drugs, anti-inflammation therapies, anti-senescence therapies, mineralocorticoid receptor antagonists, and stem cell therapies have demonstrated their potential to alleviate renal tubular injury in DKD. This review will provide insights into the latest research on the mechanisms and treatments of renal tubular injury in DKD.

show abstract

Section: Treatmentmentioning

confidence: 99%

Tubular injury in diabetic kidney disease: molecular mechanisms and potential therapeutic perspectives

et al. 2023

View full text Add to dashboard Cite

show abstract

“…UC-MSCs improve oxidative damage and apoptosis in the kidneys of DN rats. UC-MSCs can activate the PI3K/Akt signaling pathway, causing nuclear factor erythroid 2-related factor 2 (Nrf2) to translocate to the nucleus and promote downstream factor expression, which in turn inhibits proapoptotic proteins such as Bax and caspase3 and upregulates heme oxygenase-1 (HO-1) and superoxide dismutase 2 (SOD2) levels [ 44 ]. However, the specific way in which UC-MSCs affect the PI3K/Akt signaling pathway was not demonstrated.…”

Section: Studies On the Mechanism Of Mscs For The Treatment Of Dm And...mentioning

confidence: 99%

Research Progress on Mesenchymal Stem Cells for the Treatment of Diabetes and Its Complications

Zhang

Zheng

Huang

et al. 2023

International Journal of Endocrinology

View full text Add to dashboard Cite

Diabetes mellitus (DM) is a chronic disease that threatens human health. Although many drugs are available to treat DM, various complications caused by DM are unavoidable. As an emerging treatment for DM, mesenchymal stem cells (MSCs) have shown many advantages and are gradually gaining public attention. This review summarizes the clinical studies on the use of MSCs to treat DM and the potential mechanisms of complications such as pancreatic dysfunction, cardiovascular lesions, renal lesions, neurological lesions, and trauma repair. This review focuses on the research progress on MSC-mediated secretion of cytokines, improvements in the microenvironment, repair of tissue morphology, and related signaling pathways. At present, the sample sizes in clinical studies of MSCs in treating DM are small, and there is a lack of standardized quality control systems in the preparation, transportation, and infusion methods, so we need to conduct more in-depth studies. In conclusion, MSCs have shown superior potential for use in the treatment of DM and its complications and will hopefully become a novel therapeutic approach in the future.

show abstract

“…In addition to possess the function of MSCs, the adverse reactions of MSCs can be avoided to a certain extent by their extracellular vesicles (EVs), including exosomes with a diameter of 30–120 nm, and micro-vesicles ranging from 100 nm to 1 μm in size. Mounting evidence supports that MSCs released vesicles (MSCs-EVs), which may have greater clinical application potential than that of MSCs [ 14 ]. In recent years, MSC-Exo is becoming a novel and promising cell-free therapeutic agent in many ongoing clinical studies Several clinical research revealed that MSC-Exos could against different diseases, including kidney diseases, osteoarthritis, stroke, Alzheimer’s disease and type 1 diabetes [ 15–18 ].…”

Section: Introductionmentioning

confidence: 99%

Mesenchymal stem cell-derived exosomes ameliorate diabetic kidney disease through NOD2 signaling pathway

Wang,

Lu,

et al. 2024

Renal Failure

View full text Add to dashboard Cite

Background and aims Diabetic kidney disease (DKD) is one of the most common complications of diabetes. It is reported that mesenchymal stem cells (MSCs) derived exosomes (MSCs-Exo) may have great clinical application potential for the treatment of DKD, but the underlying mechanism has not been illustrated. To clarify the effect of MSC-Exo on NOD2 signaling pathway in podocytes under high glucose (HG) and DKD, we conduct this study. Methods We co-cultured podocytes and MSCs-Exo under 30 mM HG and injected MSCs-Exo into DKD mice, then we detected the NOD2 signaling pathway by western blot, qRT-PCT, immunofluorescence, transmission electron microscopy and immunohistochemistry both in vitro and in vivo . Results In vitro , HG lead to the apoptosis, increased the ROS level and activated the NOD2 signaling pathway in podocytes, while MSCs-Exo protected podocytes from injury reduced the expression of inflammatory factors including TNF-α, IL-6, IL-1β, and IL-18 and alleviated the inflammatory response, inhibited the activation of NOD2 signaling pathway and the expression of it’s downstream protein p-P65, p-RIP2, prevented apoptosis, increased cell viability in podocytes caused by HG. In vivo , MSCs-Exo alleviated renal injury in DKD mice, protected renal function, decreased urinary albumin excretion and inhibited the activation of NOD2 signaling pathway as well as the inflammation in renal tissue. Conclusion MSCs-Exo protected the podocytes and DKD mice from inflammation by mediating NOD2 pathway, MSCs-Exo may provide a new target for the treatment of DKD.

show abstract

An overview of the efficacy and signaling pathways activated by stem cell-derived extracellular vesicles in diabetic kidney disease

Cited by 3 publications

References 86 publications

Tubular injury in diabetic kidney disease: molecular mechanisms and potential therapeutic perspectives

Tubular injury in diabetic kidney disease: molecular mechanisms and potential therapeutic perspectives

Research Progress on Mesenchymal Stem Cells for the Treatment of Diabetes and Its Complications

Mesenchymal stem cell-derived exosomes ameliorate diabetic kidney disease through NOD2 signaling pathway

Contact Info

Product

Resources

About